Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Ulixertinib||Phase I||Actionable||In a Phase I trial, BVD-523 (Ulixertinib) displayed safety and preliminary efficacy in advanced solid tumor patients (J Clin Oncol 33, 2015 (suppl; abstr 2506)).||detail...|
|PubMed Id||Reference Title||Details|
|Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors||Full reference...|